Presurgical therapy in renal cell carcinoma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Since 2005, there has been a proliferation of molecularly targeted agents for the treatment of metastatic renal cell carcinoma. The necessity and timing of cytoreductive nephrectomy remains to be defined in the context of treatment with molecularly targeted agents. This chapter explores data on the safety and efficacy of molecularly targeted agents administered before cytoreductive nephrectomy, the unmet clinical needs, the key research questions, and the infrastructure required to definitively answer the questions of how to integrate cytoreductive surgery and systemic therapy in the treatment of patients with metastatic renal cell carcinoma.

Original languageEnglish (US)
Title of host publicationKidney Cancer
Subtitle of host publicationPrinciples and Practice
PublisherSpringer Berlin Heidelberg
Pages241-248
Number of pages8
ISBN (Electronic)9783642218583
ISBN (Print)9783642218576
DOIs
StatePublished - Jan 1 2012

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Presurgical therapy in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this